ACHIEVE - Aldosterone bloCkade for Health Improvement EValuation in End-stage renal disease

A randomized placebo controlled trial to assess the safety and efficacy of spironolactone on cardiovascular outcomes among patients with end-stage renal disease.

The primary objective is to determine if spironolactone reduces cardiac morbidity and mortality for patients treated with chronic dialysis.

Sample Size: Globally 2750 participants & 500 participants from India.

Study Update: In India, 168 patients are into run-in and 98 patients have been randomized.

                                                                                                                                                                                                             Updated as of 2nd Sep, 2020

سایت بازی انفجار